Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
801-820 of 1,738 trials

Gastric Cancer: New Drug Combinations

We are studying new combinations of medications alongside chemotherapy for people with advanced gastric or gastroesophageal junction cancer. The goal is to see if these combinations improve treatment outcomes and safety.

Gastric AdenocarcinomaEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Advanced High-Grade Osteosarcoma: OMO-103 Treatment Study

We are testing a new drug, OMO-103, to see if it can help treat advanced high-grade osteosarcoma in patients aged 12-15. The study will assess its safety and how it impacts the patients' quality of life.

Metastatic Osteosarcoma3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Mucopolysaccharidosis Type II: DNL310 vs Idursulfase

We are studying a new treatment, DNL310, for children and young adults with Mucopolysaccharidosis Type II to see if it works better than the current treatment, Idursulfase, in improving brain and physical health.

Hunter's Syndrome>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyNeurology

Acute Myeloid Leukemia: Venetoclax and Azacitidine with Cusatuzumab

We are studying whether adding cusatuzumab to standard treatment helps newly diagnosed AML patients who can't have intensive therapy. This trial will also look at the safety and effectiveness of this combination.

Acute Myeloid LeukemiaEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Neuroendocrine Tumors: Lutathera® Treatment Study

We are studying whether additional cycles of Lutathera® can help patients with new progression of intestinal well-differentiated neuroendocrine tumors. This trial compares the treatment to active monitoring to see which approach is more effective.

Neuroendocrine Tumor>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Systemic Sclerosis Prevention: Clopidogrel Study

We are investigating if Clopidogrel can reduce the risk of developing systemic sclerosis in patients with specific immune conditions and Raynaud phenomenon. The study compares its effects to a placebo over several years.

Raynaud Phenomenon>2 yearsEfficacy phase (II)Confirmation phase (III)Investigational MedicinesInternal MedicineRheumatology

The LIFE-MET Study: Metformin and Lifestyle Changes in Early Puberty

We are investigating how Metformin and lifestyle interventions may influence growth and development in girls with overweight and early puberty. The study looks at changes in body composition and pubertal progression.

Precocious Puberty and Overweight1-2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesPartially RemoteEndocrinologyPediatrics

Takotsubo Syndrome: Cyclosporine A Treatment Study

We are investigating whether cyclosporine A can help reduce heart damage in patients with Takotsubo syndrome compared to a placebo. This study aims to improve treatment options for this heart condition.

Healthy Participants>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesCardiologyInternal Medicine

Advanced Prostate Cancer: Debio 4228 Study

We are testing a new medication, Debio 4228, to see if it effectively lowers hormone levels in men with advanced prostate cancer. The study will also look at how well the medication is tolerated and its safety profile.

Advanced Prostate Cancer6-12 monthsEfficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyUrology

Treatment-Resistant PTSD: Mifepristone Study

We are investigating whether mifepristone can help reduce symptoms in people with treatment-resistant PTSD. This study compares its effects to a placebo to see if it offers better relief.

Post-traumatic Stress Disorder≤3 monthsEfficacy phase (II)Standard MedicinesPsychiatry

Simvastatin for Primary Sclerosing Cholangitis (PSC)

We are studying whether simvastatin can help people with PSC live longer without serious complications like bile duct cancer or the need for a transplant. We will also examine its effects on disease markers and symptoms.

Primary Sclerosing Cholangitis>2 yearsEfficacy phase (II)Standard MedicinesHepatologyOncology

Ovarian and Lung Cancer: TUB-040 Treatment Study

We are investigating a new antibody-guided drug for patients with therapy-resistant ovarian or lung cancer. The study aims to assess its safety and how well it works compared to existing treatments.

Platinum-Resistant High-Grade Ovarian Cancer and Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementGynecology and ObstetricsOncologyPulmonology

Obsessive-Compulsive Disorder: Pramipexole Treatment Study

We are investigating whether pramipexole can improve treatment outcomes for individuals with resistant OCD. The study will also assess the safety of this medication and its effects on brain function.

Obsessive-Compulsive Disorder (OCD)6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesPsychiatry

Chronic Myelomonocytic Leukemia: New Treatment Combination Study

We are testing a combination of azacitidine, venetoclax, and tagraxofusp for patients with higher-risk chronic myelomonocytic leukemia. The study aims to evaluate how well this treatment works and its safety.

Chronic Myelomonocytic Leukemia1-2 yearsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesHematologyOncology

Calcium Absorption: Glycocholate and Butyrate Study

We are testing the safety and tolerability of glycocholate and butyrate in healthy women who have undergone Roux-en-Y gastric bypass. This study aims to see if these substances can help improve calcium absorption.

Postoperative Obesity≤3 monthsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteEndocrinologyGastroenterology

Ribociclib for Cancer Patients: Continued Access Study

We are offering patients who previously benefited from ribociclib the chance to continue treatment. This study also aims to collect important safety information about ribociclib alone or with other investigational therapies.

Advanced CancerSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Senicapoc for Progressive Fibrotic Interstitial Lung Disease

We are studying whether Senicapoc can help slow the progression of lung disease in patients with progressive fibrotic ILD. This trial compares its effects to a placebo alongside standard care.

Interstitial Pulmonary Fibrosis6-12 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesPulmonology

Non-Small Cell Lung Cancer: Immunotherapy and Chemotherapy Study

We are studying a treatment combining immunotherapy, chemotherapy, and radiotherapy for patients with newly diagnosed non-small cell lung cancer that has spread to a few other areas. The aim is to see if this approach helps patients live longer without their cancer worsening.

Non-small Cell Lung Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncologyPulmonology

Triple Negative Breast Cancer: Imatinib Study

We are investigating whether Imatinib can convert triple negative breast cancer into a more treatable ER-positive type. The study also examines the safety of the drug and its effects on related cancer markers.

Triple Negative Breast CancerPrimary Breast Cancer1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOncology

Cystic Fibrosis: SPL84 Inhalation Treatment

We are testing a new inhaled medication, SPL84, for patients with cystic fibrosis to see if it is safe and how well it works. This study will help us understand its effects on this specific group of patients.

Cystic Fibrosis3-6 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesInternal MedicinePulmonology